Flavopiridol was the first serine/threonine kinase inhibitor in clinical trials and is currently tested in clinical chronic lymphocytic leukemia (CLL), AML, and CML trials. This evidence concerns the gene MARK2 and B-cell chronic lymphocytic leukemia.